Literature DB >> 19912264

BRCA1 5272-1G>A and BRCA2 5374delTATG are founder mutations of high relevance for genetic counselling in breast/ovarian cancer families of Spanish origin.

M Infante1, M Durán, A Acedo, L Pérez-Cabornero, D J Sanz, M García-González, E Beristain, E Esteban-Cardeñosa, M de la Hoya, A Teulé, A Vega, M-I Tejada, E Lastra, C Miner, E A Velasco.   

Abstract

The distribution of BRCA1 and BRCA2 germ line mutations in breast/ovarian cancer families varies among different populations, which typically present a wide spectrum of unique mutations. Splicing mutation 5272-1G>A of BRCA1 and frameshift mutation 5374delTATG of BRCA2 are highly prevalent mutations in Castilla-León (Spain), accounting for 18.4% and 13.6% of BRCA1 and BRCA2 positive families, respectively. To test the presence of founder effects, 9 Spanish 5272-1G>A and 13 5374delTATG families were genotyped with polymorphic markers linked to BRCA1 or BRCA2. All the 5272-1G>A families shared a common haplotype in eight markers (1.1 Mb region) and the mutation age was estimated in 15 generations (approximately 380 years). A conserved haplotype associated to 5374delTATG was observed in four markers (0.82 Mb). The mutation occurred approximately 48 generations ago (approximately 1200 years). Each mutation likely arose from a common ancestor that could be traced to a small area of Castilla-León and expanded to other Spanish regions. They can have a significant impact on the clinical management of asymptomatic carriers as well as on the genetic screening strategy to be followed in populations with Spanish ancestries.

Entities:  

Mesh:

Year:  2009        PMID: 19912264     DOI: 10.1111/j.1399-0004.2009.01272.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  6 in total

Review 1.  Common BRCA1 and BRCA2 mutations in breast cancer families: a meta-analysis from systematic review.

Authors:  Furu Wang; Qiaoqiao Fang; Zhen Ge; Ningle Yu; Sanxiao Xu; Xiangyong Fan
Journal:  Mol Biol Rep       Date:  2011-06-04       Impact factor: 2.316

2.  Comprehensive splicing functional analysis of DNA variants of the BRCA2 gene by hybrid minigenes.

Authors:  Alberto Acedo; David J Sanz; Mercedes Durán; Mar Infante; Lucía Pérez-Cabornero; Cristina Miner; Eladio A Velasco
Journal:  Breast Cancer Res       Date:  2012-05-25       Impact factor: 6.466

3.  BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile.

Authors:  Carolina Alvarez; Teresa Tapia; Elisa Perez-Moreno; Patricia Gajardo-Meneses; Catalina Ruiz; Mabel Rios; Claudio Missarelli; Mariela Silva; Adolfo Cruz; Luis Matamala; Luis Carvajal-Carmona; Mauricio Camus; Pilar Carvallo
Journal:  Oncotarget       Date:  2017-06-29

4.  Increased Co-Occurrence of Pathogenic Variants in Hereditary Breast and Ovarian Cancer and Lynch Syndromes: A Consequence of Multigene Panel Genetic Testing?

Authors:  Mar Infante; Mónica Arranz-Ledo; Enrique Lastra; Luis Enrique Abella; Raquel Ferreira; Marta Orozco; Lara Hernández; Noemí Martínez; Mercedes Durán
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

5.  Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain).

Authors:  Pilar Blay; Iñigo Santamaría; Ana S Pitiot; María Luque; Marta G Alvarado; Ana Lastra; Yolanda Fernández; Angeles Paredes; José M P Freije; Milagros Balbín
Journal:  BMC Cancer       Date:  2013-05-17       Impact factor: 4.430

6.  Founder BRCA1/2 mutations in the Europe: implications for hereditary breast-ovarian cancer prevention and control.

Authors:  Ramūnas Janavičius
Journal:  EPMA J       Date:  2010-06-27       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.